Screener
Immunovant, Inc. IMVT Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Other clinical and nonclinical | 3,367 | 9,327 | 39,811 |
| Other unallocated research and development | 43,856 | 44,264 | 24,562 |
| Contractual costs related to batoclimab program discontinuation | 38,952 | — | — |
| Personnel-related research and development (1) | 128,534 | 111,499 | 74,290 |
| Acquired in-process research and development | — | — | 12,500 |
| Personnel-related general and administrative (2) | 48,730 | 41,095 | 34,684 |
| Other general and administrative (3) | 27,512 | 36,140 | 22,597 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s business segments — R&D?
- Immunovant, Inc. (IMVT) reported business segments — R&D of $29.22M in Q1 2026.
- How has Immunovant, Inc.'s business segments — R&D changed year-over-year?
- Immunovant, Inc.'s business segments — R&D decreased by 6.2% year-over-year, from $31.15M to $29.22M.
- What is the long-term trend for Immunovant, Inc.'s business segments — R&D?
- Over 3 years (2023 to 2026), Immunovant, Inc.'s business segments — R&D has grown at a 35.1% compound annual growth rate (CAGR), from $52.1M to $128.53M.
- What does business segments — R&D mean?
- Represents the total costs incurred by the business segment for scientific research and the development of new pharmaceutical products or therapies. This metric captures the investment in clinical trials, laboratory testing, and regulatory activities necessary to bring pipeline assets to market. It is a primary indicator of the company's commitment to innovation and long-term product pipeline growth.
Ask your AI about Immunovant, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude